GSK’s (GSK) “Hold” Rating Reiterated at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reissued their hold rating on shares of GSK (LON:GSK) in a research note published on Tuesday,Digital Look reports. The firm currently has a GBX 2,000 price target on the stock.

Other equities analysts have also recently issued research reports about the stock. Berenberg Bank increased their price objective on shares of GSK from GBX 2,000 to GBX 2,200 and gave the stock a “hold” rating in a research note on Tuesday. Royal Bank Of Canada restated a “sector perform” rating and set a GBX 1,975 target price on shares of GSK in a research report on Tuesday, September 8th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,500 target price on shares of GSK in a report on Wednesday, July 29th. Two analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of GBX 2,064.38.

GSK Stock Up 1.8%

GSK stock opened at GBX 1,900 on Tuesday. The company has a market cap of £76.13 billion, a price-to-earnings ratio of 16.13, a P/E/G ratio of 1.24 and a beta of 0.29. The company has a debt-to-equity ratio of 103.36, a quick ratio of 0.73 and a current ratio of 0.82. The business’s 50-day moving average is GBX 1,892.75 and its two-hundred day moving average is GBX 1,957.30. GSK has a fifty-two week low of GBX 1,455 and a fifty-two week high of GBX 2,282.

GSK (LON:GSK) last released its quarterly earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share (EPS) for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. As a group, analysts forecast that GSK will post 175.980975 earnings per share for the current year.

Insider Activity

In related news, insider Jeannie Lee acquired 802 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were purchased at an average price of GBX 5,069 per share, with a total value of £40,653.38. Also, insider Vishal Sikka acquired 1,266 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was bought at an average cost of GBX 5,069 per share, for a total transaction of £64,173.54. Insiders have acquired 2,075 shares of company stock valued at $10,495,313 in the last three months. 0.20% of the stock is currently owned by corporate insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.